Illinois Compiled Statutes
ILCS Listing
Public
Acts Search
Guide
Disclaimer
Information maintained by the Legislative
Reference Bureau
Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process.
Recent laws may not yet be included in the ILCS database, but they are found on this site as Public
Acts soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the
Guide.
Because the statute database is maintained primarily for legislative drafting purposes,
statutory changes are sometimes included in the statute database before they take effect.
If the source note at the end of a Section of the statutes includes a Public Act that has
not yet taken effect, the version of the law that is currently in effect may have already
been removed from the database and you should refer to that Public Act to see the changes
made to the current law.
720 ILCS 570/216 (720 ILCS 570/216) (Text of Section before amendment by P.A. 103-881 ) Sec. 216. Ephedrine. (a) The following drug products containing ephedrine, its salts, optical
isomers and salts of optical isomers shall be exempt from the application of
Sections 312 and 313 of this Act if they: (i) may lawfully be sold
over-the-counter
without a prescription under the Federal Food, Drug, and Cosmetic Act; (ii) are
labeled and marketed in a manner consistent with Section 341.76 of Title 21 of
the Code of
Federal Regulations; (iii) are
manufactured and distributed for legitimate medicinal use in a manner that
reduces or eliminates the likelihood of abuse; and (iv) are not marketed,
advertised, or labeled for the indications of stimulation, mental alertness,
weight loss, muscle enhancement, appetite control, or energy: (1) Solid oral dosage forms, including soft gelatin | | caplets, which are formulated pursuant to 21 CFR 341 or its successor, and packaged in blister packs of not more than 2 tablets per blister.
|
| (2) Anorectal preparations containing not more than
| | (b) The marketing, advertising, or labeling of any product containing
ephedrine, a salt of ephedrine, an optical isomer of ephedrine, or a salt of an
optical isomer of ephedrine, for the indications of stimulation, mental
alertness, weight loss, appetite control, or energy, is prohibited. In
determining compliance with this requirement the Department may consider the
following factors:
(1) The packaging of the drug product;
(2) The name and labeling of the product;
(3) The manner of distribution, advertising, and
| | promotion of the product;
|
| (4) Verbal representations made concerning the
| | (5) The duration, scope, and significance of abuse or
| | misuse of the particular product.
|
| (c) A violation of this Section is a Class A misdemeanor. A second or
subsequent violation of this Section is a Class 4 felony.
(d) This Section does not apply to dietary supplements, herbs, or other
natural products, including concentrates or extracts, which:
(1) are not otherwise prohibited by law; and
(2) may contain naturally occurring ephedrine,
| | ephedrine alkaloids, or pseudoephedrine, or their salts, isomers, or salts of isomers, or a combination of these substances, that:
|
| (i) are contained in a matrix of organic
| | (ii) do not exceed 15% of the total weight of the
| | (e) Nothing in this Section limits the scope or terms of the Methamphetamine Precursor Control Act.
(Source: P.A. 94-694, eff. 1-15-06.)
(Text of Section after amendment by P.A. 103-881 )
Sec. 216. Ephedrine.
(a) The following drug products containing ephedrine, its salts, optical isomers and salts of optical isomers shall be exempt from the application of Sections 312 and 313 of this Act if they: (i) may lawfully be sold over-the-counter without a prescription under the Federal Food, Drug, and Cosmetic Act; (ii) are labeled and marketed in a manner consistent with Section 341.76 of Title 21 of the Code of Federal Regulations; (iii) are manufactured and distributed for legitimate medicinal use in a manner that reduces or eliminates the likelihood of abuse; and (iv) are not marketed, advertised, or labeled for the indications of stimulation, mental alertness, weight loss, muscle enhancement, appetite control, or energy:
(1) Solid oral dosage forms, including soft gelatin
| | caplets, which are formulated pursuant to 21 CFR 341 or its successor, and packaged in blister packs of not more than 2 tablets per blister.
|
| (2) Anorectal preparations containing not more than
| | (b) The marketing, advertising, or labeling of any product containing ephedrine, a salt of ephedrine, an optical isomer of ephedrine, or a salt of an optical isomer of ephedrine, for the indications of stimulation, mental alertness, weight loss, appetite control, or energy, is prohibited. In determining compliance with this requirement the Department may consider the following factors:
(1) The packaging of the drug product;
(2) The name and labeling of the product;
(3) The manner of distribution, advertising, and
| | promotion of the product;
|
| (4) Verbal representations made concerning the
| | (5) The duration, scope, and significance of misuse
| | of the particular product.
|
| (c) A violation of this Section is a Class A misdemeanor. A second or subsequent violation of this Section is a Class 4 felony.
(d) This Section does not apply to dietary supplements, herbs, or other natural products, including concentrates or extracts, which:
(1) are not otherwise prohibited by law; and
(2) may contain naturally occurring ephedrine,
| | ephedrine alkaloids, or pseudoephedrine, or their salts, isomers, or salts of isomers, or a combination of these substances, that:
|
| (i) are contained in a matrix of organic
| | (ii) do not exceed 15% of the total weight of the
| | (e) Nothing in this Section limits the scope or terms of the Methamphetamine Precursor Control Act.
(Source: P.A. 103-881, eff. 1-1-25.)
|
|